Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Trial Profile

A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 May 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Everolimus
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METEOR
  • Sponsors Exelixis
  • Most Recent Events

    • 31 May 2020 Results of post-hoc pooled analysis of patients who had received prior IO therapy from METEOR and C2001 presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 25 Mar 2020 According to an Exelixis media release, the company announced that Takeda Pharmaceutical Company Limited (Takeda) has received approval from the Japanese Ministry of Health, Labor and Welfare to manufacture and market CABOMETYX as a treatment for patients with curatively unresectable or metastatic renal cell carcinoma (RCC). The approval is based on the results of three clinical trials: METEOR, CABOSUN and Cabozantinib-2001.
    • 27 Dec 2019 Results assessing efficacy and safety outcomes published in the European Journal of Cancer
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top